K. Dahl et al.
Figure 3. Microfluidic apparatus setup, (P3) 18F-/K+/K222 complex solution; (P1) precursor solution; (P2) amine precursor solution.
(Waters, Sep-pak tC18 PLUS) using the following procedure: The crude flow rate; 30 ml/min). Amine solution (40 ml) and the crude reaction
reaction mixture was diluted with 25 ml H2O before it was pushed through mixture solution from step one (40 ml) was simultaneously dispensed
the SPE. The isolated product ([18F]2) was eluted with 2ml of ethanol. The through a micro-reactor (100 mm i.d., 4 m long; internal volume 31.4 ml),
radiochemical purity was established with radio-HPLC.
the micro-reactor was kept at 175ꢀC and a set flow rate of 30 ml/min.
Radiochemical purities were analyzed by analytical radio-HPLC.
Microfluidic optimization of [18F]5 and [18F]6
Solutions of 4-trimethylammoniumbenzaldehyde triflate precursor
(4.8 mM) in MeCN (400 ml), dry [18F]F-/K+/K222 solution in MeCN (400 ml)
and a solution of amine (10–140 mM, 3 or 4), sodium cyanoborohydride
(8 mg, 127.3 mmol), acetic acid (10 ml, 158.7 mmol) in MeOH (400 ml), was
loaded onto their respective storage loop. The radiolabelling step condi-
tions were kept constant (reagent volume, 20 ml; temperature, 160ꢀC;
syringe flow rate, 30 ml/min). Amine solution (40 ml) and the crude reac-
tion mixture solution from step one (40 ml) was simultaneously dispensed
through a micro-reactor (100mm i.d., 4m long; internal volume 31.4 ml), the
micro-reactor was kept at a fixed temperature (100–175ꢀC) using a set
flow rate of 30 ml/min. Radiochemical purities were analyzed by analytical
radio-HPLC.
Acknowledgements
Thanks to all the members of the PET group at Karolinska Institutet.
Conflict of Interest
The authors did not report any conflict of interest.
References
[1] G. Antoni, B. Langstrom, Handb. Exp. Pharmacol. 2008, 177.
[2] C. Halldin, B. Gulyas, L. Farde, Ernst Schering Res. Found. Workshop
2004, 95.
[3] P. W. Miller, N. J. Long, R. Vilar, A. D. Gee, Angew. Chem. Int. Ed Engl.
2008, 47, 8998.
Batch production of [18F]6
[
18F]6 was synthesized in a full scale two-step production. Solutions of
[4] S. Y. Lu, P. Watts, F. T. Chin, J. Hong, J. L. Musachio, E. Briard, V. W.
Pike, Lab Chip 2004, 4, 523.
[5] A. M. Elizarov, Lab Chip 2009, 9, 1326.
[6] S. Marre, K. F. Jensen, Chem. Soc. Rev. 2010, 39, 1183.
[7] M. Brivio, W. Verboom, D. N. Reinhoudt, Lab Chip 2006, 6, 329.
[8] R. L. Hartman, J. R. Naber, S. L. Buchwald, K. F. Jensen, Angew. Chem.
Int. Ed Engl. 2010, 49, 899.
[9] J. P. McMullen, M. T. Stone, S. L. Buchwald, K. F. Jensen, Angew. Chem.
Int. Ed Engl. 2010, 49, 7076.
4-trimethylammoniumbenzaldehyde triflate precursor (4.8 mM) in MeCN
(200 ml), dry [18F]F-/K+/K222 solution in MeCN (200 ml), and a solution of
amine (70 mM, 4), sodium cyanoborohydride (8 mg, 127.3 mmol), acetic
acid (10 ml, 158.7 mmol) in MeOH (400 ml) was loaded onto their respective
storage loop. Solutions used for the radiofluorination step was simulta-
neously infused at 15 ml/min into a micro-reactor (100 mm i.d., 2 m long;
internal volume 15.7ml), the micro-reactor was kept at a fixed temperature
of 160ꢀC. Furthermore, amine solution and the crude reaction mixture
solution from step one was dispensed simultaneously through a micro- [10] S. Lu, A. M. Giamis, V. W. Pike, Curr. Radiopharm. 2009, 2, 49.
[11] G. Pascali, G. Mazzone, G. Saccomanni, C. Manera, P. A. Salvadori,
Nucl. Med. Biol. 2010, 37, 547.
[12] G. Pascali, G. Nannavecchia, S. Pitzianti, P. A. Salvadori, Nucl. Med.
Biol. 2011, 38, 637.
[13] S. Y. Lu, V. W. Pike, Ernst Schering Res. Found. Workshop 2007, 271.
[14] P. W. Miller, H. Audrain, D. Bender, A. J. de Mello, A. D. Gee, N. J. Long,
R. Vilar, Chem. Eur. J. 2011, 17, 460.
[15] P. W. Miller, N. J. Long, A. J. de Mello, R. Vilar, H. Audrain, D. Bender,
J. Passchier, A. Gee, Angew. Chem. Int. Ed Engl. 2007, 46, 2875.
[16] S. Kealey, C. Plisson, T. L. Collier, N. J. Long, S. M. Husbands,
L. Martarello, A. D. Gee, Org. Biomol. Chem. 2011, 9, 3313.
[17] H. Audrain, Angew. Chem. Int. Ed Engl. 2007, 46, 1772.
[18] A. M. Elizarov, R. M. van Dam, Y. S. Shin, H. C. Kolb, H. C. Padgett,
D. Stout, J. Shu, J. Huang, A. Daridon, J. R. Heath, J. Nucl. Med.
2010, 51, 282.
[19] C. C. Lee, G. Sui, A. Elizarov, C. J. Shu, Y. S. Shin, A. N. Dooley, J. Huang,
A. Daridon, P. Wyatt, D. Stout, H. C. Kolb, O. N. Witte, N. Satyamurthy,
J. R. Heath, M. E. Phelps, S. R. Quake, H. R. Tseng, Science 2005,
310, 1793.
reactor (100 mm i.d., 4 m long; internal volume 31.4ml), the micro-reactor
was kept at a fixed temperature 175ꢀC using a set flow rate of 30 ml/min.
The overall labelling occurred as a single process without any intermediate
purification (Figure 3). The crude reaction mixture was purified and isolated
using preparative liquid chromatography. The specific radioactivity and
radiochemical purity of the final product was established with HPLC-UV
respective radio-HPLC, and the identification of synthesized compound
was confired by LC-MS of associated carrier [m/z = 270.16 (M+ 1)+] in the
formulated preparation.
Synthesis of [18F]AZ12439516 ([18F]8)
Solutions of 4-trimethylammoniumbenzaldehyde triflate precursor
(4.8 mM) in MeCN (400 ml), dry [18F]F-/K+/K222 solution in MeCN (400 ml),
and a solution of amine (70 mM, 7), sodium cyanoborohydride (8 mg,
127.3 mmol), acetic acid (10 ml, 158.7 mmol) in MeOH (400 ml) was loaded
onto their respective storage loop. The radiolabeling step conditions
were kept constant (reagent volume, 20 ml; temperature, 160ꢀC; syringe
Copyright © 2012 John Wiley & Sons, Ltd.
J. Label Compd. Radiopharm 2012, 55 455–459